Abstract
The objective of this work was to compare the pharmacokinetic parameters of piroxicam-β-cyclodextrin (PIX-CD) complex at molar ratio of 1:1, 1:2.5, 1:3, and 1:4 after an oral administration in rabbits and either to prove or not the Haborn et al. theory which states that the peak plasma concentration (Cmax) of piroxicam increases with an increase of β-cyclodextrin concentration. The results showed an increase in Cmax from 11 ± 1.7, 13.3 ± 6.17 to 17 ± 2.03 μg/ml for piroxicam alone, 1:1 (PIX-CD) and 1:2.5 (PIX-CD), respectively, and declined starting at molar ratio of 1:3 (PIX-CD). However, more rapid drug absorption was observed where the time of peak plasma concentration (Tmax) became shorter and changed from 2 h (Piroxicam alone) to 0.5 h in the presence of cyclodextrin.
Similar content being viewed by others
References
Loftsson, Thorsteinn, Jarho, Pekka, Masson, Mar, Järvinen, Tomi: Cyclodextrins in drug delivery. Expert opinion. Drug Deliv. 2, 335–351 (2005)
Saharan, Vikas A., Kukkar, Vipin, Kataria, Mahesh, Gera, Manoj, Choudhury, Pratim k: Dissolution Enhancement of drugs. Part I: technologies and effect of carriers. Int. J. Health 2(2), 107–124 (2009)
Bhupendra, G., Prajapati, M., Patel, M.: Conventional and alternative pharmaceutical methods to improve oral bioavailability of lipophilic drugs. Asian J. Pharm. 1(1), 1–8 (2007)
Loftsson, Thorsteinn, Brewster, Marcus E., Màsson, Màr: Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv. 2(4), 261–275 (2004)
Hardman, J.G., Limbird, L.E.: Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 9th edn, p. 713. Mc Graw Hill, New York (2001)
Moffat, A.C., Osselton, M.D., Widdop, B.Clarckes: Analysis of Drugs and Poisons, vol. 2, 3rd edn, p. 1463. Pharmaceutical Press, London (2004)
European Patent 07/16 (18/04/2007): CHIESI FARMACEUTICI S.p.a. Procédé de préparation de composés d’inclusion de piroxicam avec de la béta-cyclodextrine
Kummura, E., Bersani-Amado, C.A.: Pharmacokinetic profile of piroxicam β-CD in rat plasma and lymph. Gen. Pharmac. 28(5), 695–698 (1997)
Palma-Aguirre, Jose Antonio, Lopez-Gamboa, Mireya, Carino, Lizbeth, Burke-Fraga, Victoria, Gonzalez-de la Parra, Mario: Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, Randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers. Clin. Ther. 32(2), 357–364 (2010)
Wiseman, E.H., Hobbs, D.C.: Review of pharmacokinetic studies of piroxicam. J. Am. Med. 72, 9–17 (1982)
Brogden, R.N., Heel, R.C., Speight, T.M., et al.: Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drug 22, 165–187 (1981)
Hobbs, D.C., Twomey, T.M.: Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J. Clin. Pharmacol 19, 270–281 (1979)
Schiantarelli, P., Cadel, S.: Piroxicam pharmacologic activity and gastrointestinal damage by oral and rectal route. Arzneim. Forsch 31, 87–92 (1981)
Dalmora, M.E., Dalmora, S.L., Oliveira, A.G.: Inclusion complex of piroxicam with β-cyclodextrin and incorporation in cationic micro emulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int. J. Pharm. 22, 45–55 (2001)
Damiani, P.C., Bearzotti, M., Cabezon, M., Olivieri, A.C.: J. Pharm. Biomed. Anal. 17, 233–236 (1998)
Carrier, Rebecca L.: The utility of cyclodextrins for enhancing oral bioavailability. J. Controlled Release 123, 78–79 (2007)
Brewster, Marcus E.: Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645–666 (2007)
Rajeswari, Challa.: Cyclodextrins in drug delivery: an updated review AAPS Pharm Sci Tech, 6 (2) article 43 (2005)
Shimpi, Shyam, Chauhan, Bhaskar, Shimpi, Prajakta: Cyclodextrins: application in different routes of drug administration. Acta Pharm. 55, 139–156 (2005)
Loftsson, Thorsteinn, Masson, Mar: Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. 225, 15–30 (2001)
Oda, Masako, Saitoh, Hiroshi, Kobayashi, Michiya, Aungst, Bruce J.: β-CD as a suitable solubilizing agent for in situ absorption study of poorly water soluble drugs. Int. J. Pharm. 280, 95–102 (2004)
Osadebe, P.O.: Energetic of the interaction between piroxicam and β-CD in inclusion complexes. Sci. Res. Essays 3(3), 86–93 (2008)
Xiliang, Guo., Yu, Yang.: Study on inclusion interaction of piroxicam with β-CD derivatives. Spectrochimica Acta Part A 59 (2003)
Cavallari, Cristina: Improved dissolution behavior steam-granulated piroxicam. Eur. J. Pharm. Biopharm. 54, 65–73 (2002)
Rozou, Stavroula: The effect of pH dependent molecular conformation and dimerization phenomena of piroxicam on the drug: cyclodextrin complex stoichiometry and its chromatographic behavior. A new specific HPLC method for piroxicam: cyclodextrin formulations. Eur. J. Pharm. Sci. 21, 661–669 (2004)
Vanhees, Thierry: Determination of the free/included piroxicam ratio in CD complexes: comparison between UV spectrophotometry and differential scanning calorimetry. Eur. J. Pharm. Sci. 15, 347–353 (2002)
Acerbi, D.: Pharmacokinetic profile of piroxicam β-CD. Drug Invest. 2, 42–49 (1990)
Szejtli, Jozset: Past, present and future of cyclodextrin research. Pure Appl. Chem. 76(10), 1825–1845 (2004)
Haborn, I., Ricketts, D., Szejtli, J.: Simulation of pharmacokinetic behavior of drug-cyclodextrin complexes. Pharmazie 39, 830–834 (1984)
Palomares-Alonso, Francisca, et al.: Two ternary albendazole-cyclodextrin-polymer systems: dissolution, bioavailability and efficacy agains Taenia crassiceps cysts. Acta Trop. 113, 56–60 (2010)
Fawaz, F., et al.: Bioavailability of norfloxacin from PEG6000 solid dispersion and cyclodextrin inclusion complexes in rabbits. Int. J. Pharm. 132, 271–275 (1996)
Kedzierewicz, F., et al.: Bioavailability study of tolbutamide β-CD inclusion compounds, solid dispersions and bulk powder. Int. J. Pharm. 94, 69–74 (1993)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skiba, M., Bouchal, F., Boukhris, T. et al. Pharmacokinetic study of an oral piroxicam formulation containing different molar ratios of β-cyclodextrins. J Incl Phenom Macrocycl Chem 75, 311–314 (2013). https://doi.org/10.1007/s10847-012-0166-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10847-012-0166-0